# Corner Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/corner-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: https://cornertx.com/
- Total disclosed funding: $54M
- Latest round: Series A (Apr 18, 2024)
- Investors on record: 4

## About

Based in Massachusetts, US, and founded in 2020 by CEO Steven M. Altschuler, Jonathan Kagan, and Marian R. Neutra, Corner Therapeutics, Inc., a.k.a. Corner Therapeutics operates as an immunotherapy company that focuses on developing multi-purpose immunotherapies to address a virtually unbounded range of cancers and infectious diseases. In April 2024, Corner Therapeutics raised USD 54 million in a Series A funding led by Ziff Capital Partners, with participation from Cockrell Interests, Tanis Venture Management, and Sandia Holdings.

The company offers DC Hyperactivation, an immunotherapy platform that enhances dendritic cells' intelligence to generate robust T and B cell-mediated immunity for life. By leveraging hyperactivators, the platform stimulates inflammasome activation within living dendritic cells, leading to long-lasting memory T cell production and effective disease treatment.

In addition, Corner Therapeutics utilizes a catalytic adjuvant platform to develop nucleic acid-based vaccines for infection prevention and cancer treatment. Unlike conventional mRNA-LNP vaccines, the platform enhances both cellular and humoral immunity, generating durable memory T cells and preserving antibody responses for lifelong immunity against diseases.

The company plans to use its proceeds from April 2024 funding to create vaccines that confer lifelong protection from cancer and infectious diseases.

## Funding rounds

- Series A, Apr 18, 2024, $54M — Cockrell Interests, Ziff Capital Partners, Tanis Venture Management, Sandia Holdings

## Investors

- Cockrell Interests (https://capitalatlas.ai/funds/cockrell-interests) — Series A
- Ziff Capital Partners — Series A
- Tanis Venture Management (https://capitalatlas.ai/funds/tanis-venture-management) — Series A
- Sandia Holdings — Series A